INTRODUCTION {#s1}
============

Although the incidence has declined recently, gastric cancer is still the second leading cause of cancer related--death and the 5--year survival was less than 30% \[[@R1]\]. Radical resection with D2 lymphadenectomy is the only potential curative method for RGC. However, the survival of RGC patients after D2 resection varies greatly due to different clinical pathological characteristics \[[@R2]\].

Currently, the American Joint Committee on Cancer (AJCC) classifies gastric cancer into nine groups in the 7th edition staging system \[[@R3]\]. This system assesses gastric cancer based on the depth of invasion, mLNS and the status of distant metastasis, and implies that the anatomical disease progression correlates with patients\' survival. It has been widely used to predict the survival for gastric cancer patients. However, the variation of outcomes in intrastage patients cannot be accurately predicted by this staging system \[[@R4]\], especially the individual survival for each patient. It is believed that host status and other prognostic factors such as age, race and histology could significantly affect the individual survival in some cancers \[[@R5]--[@R9]\].

Nomogram, a simple statistical predictive tool, has been constructed in gastric cancer previously and proved to be useful and effective \[[@R10]--[@R17]\]. By creating an intuitive graph, a nomogram can predict a numerical probability of a special clinical event, such as overall survival (OS), progression--free survival and time to recurrence \[[@R18]\]. As nomograms based on single population might be unapplicable to RGC patients of all regions, it is of importance that nomograms be validated in multi--population cohort before clinical application \[[@R4]\]. However, only a few nomograms predicting survival probability of RGC patients were validated in different populations \[[@R10], [@R12], [@R19]--[@R21]\].

In the present study, we aim to develop and validate a nomogram for RGC based on a multi--institution and multi--population data from SEER database which contains both western and eastern patients with RGC. Additionally, we used a separate cohort from Asia for external validation.

RESULTS {#s2}
=======

Patients and demographics {#s2_1}
-------------------------

4,379 gastric cancer patients from the SEER database between January, 2004 and December, 2012 were eligible for the present analysis (Table [1](#T1){ref-type="table"}). Overall, the median age in the primary cohort was 64.3. The most common tumor sites were cardia and antrum (35.3%, 31.5% respectively). There were 973 (22.2%) Asian or Pacific Islander (API) patients and 3,406 (77.8%) nonAPI patients. The median follow-up was 28.5 months, and the 5--year DSS was 46.6%. 2,056 (46.9%) patients died before the analysis of the present study. The 2,770 patients diagnosed between 2004 and 2009 were assigned as training set, and patient\'s clinical pathological characteristics were listed in Table [2](#T2){ref-type="table"}.

###### Characteristic of primary cohort from SEER database

  Characteristic               Patients(n= 4,379)                
  ---------------------------- -------------------- ------------ ------
  Age (years)                                                    
   Median                                           64.3±13.2    
   Range                                            14 to 96     
  Sex                                                            
   Male                        2762                              63.1
   Female                      1617                              36.9
  Race                                                           
   API                         973                               22.2
   nonAPI                      3406                              77.8
  Tumor size (cm) (n= 3,944)                                     
   Median                                           5.6±6.5      
   Range                                            0.1 to 9.5   
  Tumor location                                                 
   Cardia                      1544                              35.3
   Fundus                      192                               4.4
   Body                        562                               12.8
   Antrum                      1379                              31.5
   Pylorus                     204                               4.7
   Overlapping                 498                               11.4
  Grade                                                          
   Well differentiated         178                               4.1
   Moderately differentiated   1126                              25.7
   Poorly differentiated       2941                              67.2
   Undifferentiated            134                               3.1
  Depth of invasion                                              
   Mucosa or submucosa         777                               17.7
   Proper muscle               520                               11.9
   Subserosa                   1748                              39.9
   Serosa                      1002                              22.9
   Adjacent invasion           332                               7.6
  Number of positive LN                                          
   0                           1438                              32.8
   1 to 2                      672                               15.3
   3 to 6                      748                               17.1
   7 to 15                     938                               21.4
   16 or more                  583                               13.3
  Positive LN (Mean±SD)                             6.4±8.4      
  Total LN (Mean±SD)                                26.5±11.2    
  AJCC Stage                                                     
   IA                          587                               13.4
   IB                          346                               7.9
   IIA                         599                               13.7
   IIB                         558                               12.7
   IIIA                        556                               12.7
   IIIB                        913                               20.8
   IIIC                        820                               18.7
  Combined devisceration                                         
   Yes                         658                               15.0
   No                          3721                              85.0

Abbreviation: API, Asian or Pacific Islander; LN, lymph node; AJCC, American Joint Committee on Cancer.

###### Characteristics and multivariate analysis of the training set

                               Characteristics   Multivariate Analysis                                     
  ---------------------------- ----------------- ----------------------- ---------------- ---------------- ---------
  Age(Mean±SD year)            64.4±13.2         Range: 14 to 96         1.018            1.014 to 1.022   \<0.001
  Race                                                                                                     \<0.001
   API                         613               22.1                    1.262            1.101 to 1.447   
   nonAPI                      2157              77.9                                                      
  Location                                                                                                 \<0.001
   Antrum/Pylorus              997               36.0                    ref                               
   Body                        352               12.7                    0.961            0.799 to1.156    
   Cardia/Fundus               1111              40.1                    1.306            1.153 to 1.479   
   Overlapping                 310               11.2                    1.055            0.888 to 1.253   
  Grade                                                                                                    0.002
   Well differentiated         89                3.2                     ref                               
   Moderately differentiated   696               25.1                    1.358            0.870 to 2.121   
   Poorly differentiated       1894              68.4                    1.697            1.095 to 2.628   
   Undifferentiated            91                3.3                     1.713            1.028 to 2.854   
  Total LN (Mean±SD)           26.4±11.2         0.985                   0.980 to 0.990   \<0.001          
  Depth of invasion                                                                                        \<0.001
   Mucosa or submucosa         444               16.0                    ref                               
   Proper muscle               314               11.3                    1.502            1.094 to 2.061   
   Subserosa                   1058              38.2                    2.844            2.190 to 3.693   
   Serosa                      713               25.7                    3.155            2.411 to 4.127   
   Adjacent invasion           241               8.7                     4.387            3.269 to 5.887   
   Number of positive LN.                                                                                  \<0.001
   0                           841               30.4                    ref                               
   1 to 2                      417               15.1                    1.729            1.410 to 2.118   
   3 to 6                      456               16.5                    2.221            1.830 to 2.696   
   7 to 15                     644               23.2                    3.220            2.683 to 3.864   
   16 or more                  412               14.9                    6.126            5.018 to 7.478   

Abbreviation: API, Asian or Pacific Islander; LN, lymph node;HR:hazard ratio;

There were two external validation sets used to validate the nomogram in the present analysis. 1,609 gastric cancer patients diagnosed between 2010 and 2012 from SEER data were selected as SEER validation set. 1,385 RGC patients underwent D2 resection in SYSUCC from 2000 to 2011 were assigned as SYSUCC validation set. The clinical pathological characteristics were listed in Table [3](#T3){ref-type="table"}.

###### Characteristic of validation sets

                                 SEER-Validation set(n=1,609)   SYSUCC-Validation set(n=1,385)                    
  ------------------------------ ------------------------------ -------------------------------- ------ ------ -- ------
  Age (years)                                                                                                     
   Median                        64.0±13.2                      56.6±12.1                                         
   Range                         22 to 94                       16 to 89                                          
  Sex                                                                                                             
   Male                          1028                                                            63.9   926       66.9
   Female                        581                                                             36.1   459       33.1
  Race                                                                                                            
   API                           360                                                             22.4   1385      100
   nonAPI                        1249                                                            77.6             
  Tumor location                                                                                                  
   Antrum/Pylorus                586                                                             36.4   601       43.4
   Body                          210                                                             13.1   262       18.9
   Cardia/Fundus                 625                                                             38.8   522       37.7
   Overlapping                   188                                                             11.7             
  Grade                                                                                                           
   Well differentiated           89                                                              5.5    15        1.1
   Moderately  differentiated    430                                                             26.7   366       26.4
   Poorly differentiated         1047                                                            65.1   997       72.0
   Undifferentiated              43                                                              2.7    7         0.5
  Depth of invasion                                                                                               
   Mucosa or  submucosa          333                                                             20.7   147       10.6
   Proper muscle                 206                                                             12.8   162       11.7
   Subserosa                     690                                                             42.9   370       26.7
   Serosa                        289                                                             18.0   574       41.4
   Adjacent invasion             91                                                              5.7    132       9.5
  Number of positive LN.                                                                                          
   0                             597                                                             37.1   331       23.9
   1 to 2                        255                                                             15.8   235       17.0
   3 to 6                        292                                                             18.1   247       17.8
   7 or 15                       294                                                             18.3   355       25.6
   16 or more                    171                                                             10.6   217       15.7
  No. of Positive LN (Mean±SD)   5.4±7.8                        7.5±8.9                                           
  Total LN (Mean±SD)             26.6±11.2                      28.7±10.1                                         
  AJCC Stage                                                                                                      
   IA                            256                                                             15.9   103       7.4
   IB                            143                                                             809    94        6.8
   IIA                           264                                                             16.4   120       8.7
   IIB                           212                                                             13.2   196       14.2
   IIIA                          206                                                             12.8   163       11.8
   IIIB                          283                                                             17.6   283       20.4
   IIIC                          245                                                             15.2   426       30.8

Abbreviation: API, Asian or Pacific Islander; LN, lymph node; AJCC, American Joint Committee on Cancer.

Selected independent risk factors for the nomogram construction {#s2_2}
---------------------------------------------------------------

Clinical pathological variables were transformed and examined to fit the Cox PH regression and linear assumption before models construction. The potential variables from training set were analyzed by the forward method in multivariate analysis. As listed in the Table [2](#T2){ref-type="table"}, the patients\' age at diagnosis, race, tumor location, grade, depth of invasion, mLNS and TLN were associated with patients\' DSS (Chi--square test=1068.9, p\<0.001), and the nomogram was constructed from this model (Figure [1](#F1){ref-type="fig"}).

![Nomogram predicting 1--year, 3--year and 5--year DSS for RGC patients after curative resection\
The nomogram is used by adding up the points identified on the points scale for each variable. According to the sum of these points projected on the bottom scales, the nomogram can provide the likelihood of 1--year, 3--year and 5--year DSS for an individual patient.](oncotarget-07-35853-g001){#F1}

Validation of the nomogram {#s2_3}
--------------------------

The external validation of the nomogram was performed by two individual external validation sets (SEER validation set and SYSUCC validation set). The clinical pathological characteristics of validation sets were listed in Table [3](#T3){ref-type="table"}. The predictive ability of the nomogram was compared to the 7th edition of AJCC staging system. First, the nomogram was validated by the SEER validation set. The C--index of which was obviously higher than that of the 7th edition of AJCC staging system (0.73, 95% CI, 0.70--0.76 versus 0.70, 95% CI, 0.67--0.74; p=0.005). Second, the discrimination of the nomogram was evaluated by the SYSUCC validation set. Interestingly, the nomogram based on the western (including 77.8% nonAPI) population also has an optimal discrimination in Asian population (C--index of nomogram: 0.76, 95%CI, 0.73--0.78 versus C--index of 7th edition of AJCC staging system: 0.72, 95%, 0.69--0.74; p= 0.005).

Next, considering that the longest follow--up of SEER validation set was 35 months, the 5--year calibration cannot be executed in SEER validation set. Therefore, the calibration plots were separately performed by the primary cohort and SYSUCC validation set. As shown in Figure [2](#F2){ref-type="fig"}, calibration plots show that the predicted 1--year, 3--year and 5--year DSS corresponded closely to the actual survival estimated by the Kaplan--Meier method in the two data sets. Additionally, we compared the 1--year, 3--year and 5--year DSS predicting ability of the two models by the AUC (area of ROC curve) in the two data sets (Figure [3](#F3){ref-type="fig"}). As shown in the Figure [3](#F3){ref-type="fig"} and Table [4](#T4){ref-type="table"}, the nomogram shows superior survival predictive ability than the 7th AJCC staging system.

###### Comparison of the areas under the ROC curves for nomogram and the 7th edition of AJCC staging system in each time points

  Time points             Nomogram   AJCC staging system   p                        
  ----------------------- ---------- --------------------- ------- ---------------- ---------
  SEER primary cohort                                                               
   1-Year                 0.774      0.756 to 0.792        0.729   0.710 to 0.747   \<0.001
   3-Year                 0.810      0.795 to 0.826        0.772   0.755 to 0.790   \<0.001
   5-Year                 0.838      0.820 to 0.856        0.791   0.769 to 0.813   \<0.001
  SYSUCC validation set                                                             
   1-Year                 0.781      0.742 to 0.820        0.733   0.694 to 0.772   0.001
   3-Year                 0.815      0.786 to 0.843        0.760   0.728 to 0.792   \<0.001
   5-Year                 0.822      0.790 to 0.855        0.783   0.745 to 0.821   \<0.001

Abbreviation: AUC, Area Under the ROC Curve; AJCC, American Joint Committee on Cancer.

![The calibration curve for predicting patients\' DSS at 1--year A. 3--year B. and 5--year C. in the SEER primary cohort and predicting DSS at 1--year D. 3--year E. and 5--year F. in the SYSUCC validation set\
The X--aixs represents the nomogram--predicted survival, and the actual survival is plotted on the Y--axis. The dotted line represents the ideal correlationship between predicted and actual survival. Abbreviation: SEER, the Surveillance, Epidemiology, and End Results cancer registries; SYSUCC, Sun Yat--sen University Cancer Center; DSS, Disease Specific Survival.](oncotarget-07-35853-g002){#F2}

![Comparison of the areas under the receiver operating curves of nomogram and AJCC to prediction of DSS at 1--year A. 3--year B. and 5--year C. in the SEER primary cohort and 1--year D. 3--year E. and 5--year F. in the SYSUCC validation set\
The red lines represent nomogram predicted DSS and the balack lines represent the AJCC staging predicted DSS. Abbreviation: SEER, the Surveillance, Epidemiology, and End Results cancer registries; SYSUCC, Sun Yat--sen University Cancer Center; DSS, Disease Specific Survival.](oncotarget-07-35853-g003){#F3}

DISCUSSION {#s3}
==========

In this study, we developed and validated a novel nomogram of RGC patients underwent curative resection to predict DSS based on general population. A total of 4,379 gastric patients from SEER database and 1,385 RGC patients from Asia were analyzed. Our nomogram showed better predictive accuracy than the 7th edition of AJCC staging system in DSS prediction for the RGC patients (C--index: 0.73 versus 0.70, p=0.005 in SEER validation set; 0.76 versus 0.72, p=0.005 in SYSUCC validation set; respectively).

Several nomograms have been constructed in RGC patients, and show more accurate survival prediction than the conventional staging system in different populations. In 2003, Kattan et al developed a nomogram to predict 5--year DSS for gastric cancer patients based on 1,136 patients from Memorial Sloan--Kettering Cancer Center (MSKCC), and Han et al developed and validated a nomogram in a cohort of 10,454 gastric cancer patients who underwent curative resection form Seoul National University Hospital (SNUH, Seoul, Korea) and Cancer Institute Ariake Hospital (Tokyo, Japan) in 2012 \[[@R19], [@R20]\]. Both MSKCC nomogram and SNUH nomogram showed that combining more clinical pathological characteristics can provide an improved accuracy for survival prediction (0.80 versus 0.77, p\<0.001; 0.78, 0.79 versus 0.69; respectively). However, the MSKCC nomogram was validated by an internal validation (bootstrap resampling), and the SNUH nomogram was developed and validated only in Asian region. Thus, it\'s unclear whether it is applicable for the general population. Actually, external validation of the nomogram is essential. This process can test the bias of the estimation of nomogram performance in different populations and judge the applicability to other different populations \[[@R18]\].

Compared with previous MSKCC nomogram and SNUH nomogram, our nomogram was developed and validated based both on western and eastern population. In this study, the race of patients was categorized as API and nonAPI. Interestingly, on the multivariate analysis, we found the nonAPI patients had a worse prognosis than API patients in the SEER data (hazard ratio: 1.337, p\<0.001), which was consistent with previous studies \[[@R6], [@R7], [@R9]\]. Indeed, even in the same TNM stage, patients from different populations might lead to various survival, the reason may be the missing prognostic factor, the race. Currently, our nomogram was first time to use the patient\'s race as one of risk factors and could predict the DSS in general population more precisely.

Improving the accuracy of the survival estimation is exceedingly important for clinical decision. There are several advantages by using nomogram. Firstly, the accurate prediction would be favor for designing postoperative treatment. For example, in 2010, a phase III trial confirmed that adjuvant chemotherapy with S1 (an oral fluoropyrimidine) was an effective treatment for advanced gastric cancer patients who underwent D2 gastrectomy \[[@R22]\]. However, it is still uncertain whether all the RGC patients, especially, the patients with better prognosis require adjuvant chemotherapy. Since our nomogram could make a more accurate prediction of individual survival than 7th edition of AJCC staging system, it may be an effective criterion for patients to design an individual postoperative treatment. Secondly, our nomogram can calculate each patient\'s 1--year, 3--year and 5--year survival rate respectively. Therefore, it has potential to be used for a more reasonable follow--up schedule. Thirdly, nomogram can be used for patients\' consultant. The variation of DSS intrastage can\'t be predicted accurately by traditional TNM--stage system. By contrast, our nomogram can provide individualized estimation for gastric cancer patients.

There are some limitations should be acknowledged. Firstly, only the patients who had complete information were included in present study, there may be a selection bias. Secondly, as this nomogram was based on SEER database, analysis was limited to the prognosis factors in the database. Several predictors such as Lauren classification, genetic differences, protein expression differences and postoperative treatments had not been included \[[@R23]--[@R25]\].

In summary, we first develop and validate a prognostic nomogram based on a multi--institution and multi--population database predicting short--term and long--term DSS for RGC patients. Compared with the 7th edition of AJCC staging system, the proposed nomogram represents better prognostic discrimination and predictive accuracy for DSS. It can be used to calculate individualized survival prediction and provide better treatment allocation after curative resection.

PATIENTS AND METHODS {#s4}
====================

Patients {#s4_1}
--------

The SEER program is a national collaboration program by the National Cancer Institute. It collects and publishes approximately 3 million cases from a variety of geographic regions and covers 26% American population\'s cancer incidence and survival data. A retrospective review of all gastric cancer patients underwent gastrectomy from SEER database between 1998 and 2012 was performed. A total of 31,988 cases from SEER 18 registries were initially screened. Patients were excluded if they had incomplete information on depth of invasion, tumor size, positive lymph node (PLN), TLN or status of distant metastasis. Given that the 7th edition of AJCC staging system bases mLNS definition on the absolute PLN and suggests that "at least 16 regional lymph node be assessed pathologically", the patients (n=8,107) with TLN less than 16 were excluded from present study \[[@R3]\]. The remaining (n= 4,379) were defined as SEER primary cohort. Based on the SEER primary cohort, patients diagnosed as gastric cancer between 1998 and 2009 were assigned as training data set, and those between 2010 and 2012 were SEER validation set.

The proposed nomogram was also externally validated by SYSUCC validation set. Of the 2,205 RGC patients who underwent D2 resection in SYSUCC between 2000 and 2011, 1,385 patients met the following inclusion criteria: no history of receiving anti--cancer therapy before surgery; no history of other malignancies; no distant metastasis; complete resection of cancer (R0 resection) with D2 lymphadenectomy; number of examined lymph more than 15; without one or more missing characteristics. The median follow-up was 36.8 months in training set, 14.0 months in SEER validation set and 36.7 months in SYSUCC validation set.

Study design {#s4_2}
------------

The data of patients\' clinicopathological characteristics such as age at diagnosis, sex, race, surgery, tumor location, size, histology, grade, depth of invasion, PLN and TLN were collected. The pathological tumor stage, depth of invasion and mLNS were restaged according to the 7th edition of AJCC staging system \[[@R3]\]. The primary endpoint was DSS, which was defined as the time form surgery to cancer--related death or the last follow--up. The follow--up duration was measured as the time from the date of surgery to the last follow--up. The survival status was recorded according to the latest follow--up.

Construction of the nomogram {#s4_3}
----------------------------

Based on clinical findings, categorical variables were grouped before modeling. Restricted cubic splines were used to evaluate the linear relationship between continuous variables and DSS \[[@R19]\]. Continuous variables were transformed into categorical variables to fit the linear assumption \[[@R20]\]. Independent risk factors were identified by the forward stepwise in the Cox proportional hazards (PH) regression model. DSS estimation and survival curves were performed by Kaplan--Meier method and validated by the log--rank test.

Nomogram was established based on the training set data. Based on the results of Cox PH regression, a nomogram combining all the independent prognostic factors was constructed for 1--year, 3--year and 5--year DSS predicting by using the package of rms in R software version 3.1.3 (<http://www.r-project.org/>).

Validation of the nomogram {#s4_4}
--------------------------

The nomogram was validated by measuring both discrimination and calibration using two separated data sets. Firstly, the discrimination of nomogram was evaluated by Harrell\'s C--index, which can estimate the probability between the observed and predicted DSS. The higher the C--index, the more precise the survival prediction was. Discrimination between the proposed nomogram and the 7th edition of AJCC staging system was performed by the roccp. cens package in R. Following, calibration were carried out by grouping all the patients firstly, and then the mean of the groups were compared with observed Kaplan--Meier DSS estimation. Finally, the precision of survival prediction in 1--year, 3--year and 5--year time points were evaluated by the area under receiver operating characteristic (ROC) curve.

p\<0.05 will be considered as statistically significant. All statistics analysis were performed by the R software version 3.13 (<http://www.r-project.org/>) and the software statistical package for social sciences version 19.0 (SPSS, Chicago, IL).
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